Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 693,633
  • Shares Outstanding, K 42,450
  • Annual Sales, $ 21,430 K
  • Annual Income, $ -78,690 K
  • 60-Month Beta 1.89
  • Price/Sales 35.75
  • Price/Cash Flow N/A
  • Price/Book 1.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.84
  • Number of Estimates 2
  • High Estimate -0.72
  • Low Estimate -0.95
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -58.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.26 +9.70%
on 01/31/20
19.15 -12.58%
on 02/19/20
+0.35 (+2.14%)
since 01/24/20
3-Month
13.63 +22.82%
on 12/02/19
19.85 -15.67%
on 12/18/19
+2.65 (+18.81%)
since 11/26/19
52-Week
9.50 +76.21%
on 10/10/19
20.84 -19.67%
on 04/23/19
-0.96 (-5.42%)
since 02/26/19

Most Recent Stories

More News
Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST

Regulatory News:

CMVLF : 18.3200 (+11.03%)
CLLS : 16.74 (+2.45%)
Cellectis and Servier Expand Collaboration on UCART19 Products

Regulatory News:

CMVLF : 18.3200 (+11.03%)
CLLS : 16.74 (+2.45%)
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage...

CMVLF : 18.3200 (+11.03%)
IOVA : 33.65 (+6.96%)
CLLS : 16.74 (+2.45%)
Cellectis:An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth:ALCLS; Nasdaq:CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells...

CMVLF : 18.3200 (+11.03%)
CLLS : 16.74 (+2.45%)
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

KEYS : 94.07 (+0.44%)
ALXN : 94.78 (-1.41%)
AMRN : 16.27 (-7.03%)
CLLS : 16.74 (+2.45%)
ADI : 114.84 (+0.16%)
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

NVS : 87.11 (-0.96%)
BMY : 62.04 (-0.16%)
ALXN : 94.78 (-1.41%)
CLLS : 16.74 (+2.45%)
MDCO : 84.90 (-0.07%)
AMRN : 16.27 (-7.03%)
1st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Regulatory News:

CMVLF : 18.3200 (+11.03%)
CLLS : 16.74 (+2.45%)
Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells

Regulatory News:

CMVLF : 18.3200 (+11.03%)
CLLS : 16.74 (+2.45%)
Cellectis Publishes Creation of "Smart CAR T-Cells" for Potentially Safer, More Effective Treatments for Cancer in Nature Communications

Regulatory News:

CMVLF : 18.3200 (+11.03%)
CLLS : 16.74 (+2.45%)
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019

Regulatory News:

CMVLF : 18.3200 (+11.03%)
CLLS : 16.74 (+2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CLLS with:

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

2nd Resistance Point 17.17
1st Resistance Point 16.95
Last Price 16.74
1st Support Level 16.39
2nd Support Level 16.05

See More

52-Week High 20.84
Last Price 16.74
Fibonacci 61.8% 16.51
Fibonacci 50% 15.17
Fibonacci 38.2% 13.83
52-Week Low 9.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar